| Identification | Back Directory | [Name]
Lapaquistat | [CAS]
189059-71-0 | [Synonyms]
T 91485 HDGUKVZPMPJBFK-LEAFIULHSA-N 4-Piperidineacetic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- | [Molecular Formula]
C31H39ClN2O8 | [MDL Number]
MFCD20270506 | [MOL File]
189059-71-0.mol | [Molecular Weight]
603.1 |
| Hazard Information | Back Directory | [Uses]
Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy[1]. | [in vivo]
After oral administration to rats, Lapaquistat Lapaquistat acetate (HY-16274) is absorbed and rapidly hydrolyzed into a pharmacological active metabolite, Lapaquistat[1]. | [References]
[1] Nishimoto T, et al. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochem Pharmacol. 2003 Dec 1;66(11):2133-9. DOI:10.1016/j.bcp.2003.08.011 |
|
|